vs
AIM ImmunoTech Inc.（AIM）与HALOZYME THERAPEUTICS, INC.（HALO）财务数据对比。点击上方公司名可切换其他公司
HALOZYME THERAPEUTICS, INC.的季度营收约是AIM ImmunoTech Inc.的21512.7倍（$451.8M vs $21.0K）。HALOZYME THERAPEUTICS, INC.净利率更高（-31.3% vs -19881.0%，领先19849.6%）。HALOZYME THERAPEUTICS, INC.同比增速更快（51.6% vs -53.3%）。过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs -27.5%）
AIM ImmunoTech是一家总部位于美国佛罗里达州奥卡拉的生物制药企业，前身是Hemispherx Biopharma，1990年成立，目前专注于研发用于治疗多种癌症、各类病毒感染以及免疫缺陷疾病的创新疗法。
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
AIM vs HALO — 直观对比
营收规模更大
HALO
是对方的21512.7倍
$21.0K
营收增速更快
HALO
高出104.9%
-53.3%
净利率更高
HALO
高出19849.6%
-19881.0%
两年增速更快
HALO
近两年复合增速
-27.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0K | $451.8M |
| 净利润 | $-4.2M | $-141.6M |
| 毛利率 | — | 82.6% |
| 营业利润率 | -14057.1% | -20.6% |
| 净利率 | -19881.0% | -31.3% |
| 营收同比 | -53.3% | 51.6% |
| 净利润同比 | 30.0% | -203.3% |
| 每股收益（稀释后） | $-6.46 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AIMHALO
| Q4 25 | $21.0K | $451.8M | ||
| Q3 25 | $26.0K | $354.3M | ||
| Q2 25 | $25.0K | $325.7M | ||
| Q1 25 | $16.0K | $264.9M | ||
| Q4 24 | $45.0K | $298.0M | ||
| Q3 24 | $35.0K | $290.1M | ||
| Q2 24 | $50.0K | $231.4M | ||
| Q1 24 | $40.0K | $195.9M |
净利润AIMHALO
| Q4 25 | $-4.2M | $-141.6M | ||
| Q3 25 | $-3.3M | $175.2M | ||
| Q2 25 | $-2.8M | $165.2M | ||
| Q1 25 | $-3.7M | $118.1M | ||
| Q4 24 | $-6.0M | $137.0M | ||
| Q3 24 | $-3.7M | $137.0M | ||
| Q2 24 | $-1.8M | $93.2M | ||
| Q1 24 | $-5.8M | $76.8M |
毛利率AIMHALO
| Q4 25 | — | 82.6% | ||
| Q3 25 | — | 84.4% | ||
| Q2 25 | — | 85.8% | ||
| Q1 25 | — | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 82.9% | ||
| Q1 24 | — | 85.5% |
营业利润率AIMHALO
| Q4 25 | -14057.1% | -20.6% | ||
| Q3 25 | -9411.5% | 61.5% | ||
| Q2 25 | -10584.0% | 62.2% | ||
| Q1 25 | -22618.8% | 53.4% | ||
| Q4 24 | -13011.1% | 58.9% | ||
| Q3 24 | -12825.7% | 56.3% | ||
| Q2 24 | -7388.0% | 50.7% | ||
| Q1 24 | -14335.0% | 48.8% |
净利率AIMHALO
| Q4 25 | -19881.0% | -31.3% | ||
| Q3 25 | -12630.8% | 49.5% | ||
| Q2 25 | -11176.0% | 50.7% | ||
| Q1 25 | -23156.3% | 44.6% | ||
| Q4 24 | -13260.0% | 46.0% | ||
| Q3 24 | -10571.4% | 47.2% | ||
| Q2 24 | -3672.0% | 40.3% | ||
| Q1 24 | -14542.5% | 39.2% |
每股收益（稀释后）AIMHALO
| Q4 25 | $-6.46 | $-1.13 | ||
| Q3 25 | $1.57 | $1.43 | ||
| Q2 25 | $-3.68 | $1.33 | ||
| Q1 25 | $-0.05 | $0.93 | ||
| Q4 24 | $-21.80 | $1.06 | ||
| Q3 24 | $-6.00 | $1.05 | ||
| Q2 24 | $-3.00 | $0.72 | ||
| Q1 24 | $-0.12 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $133.8M |
| 总债务越低越好 | $4.5M | $2.1B |
| 股东权益账面价值 | $-9.8M | $48.8M |
| 总资产 | $5.8M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 43.89× |
8季度趋势，按日历期对齐
现金及短期投资AIMHALO
| Q4 25 | $3.0M | $133.8M | ||
| Q3 25 | $2.4M | $419.7M | ||
| Q2 25 | $835.0K | $61.9M | ||
| Q1 25 | $2.2M | $176.3M | ||
| Q4 24 | $4.0M | $115.8M | ||
| Q3 24 | $7.2M | $154.3M | ||
| Q2 24 | $10.1M | $187.9M | ||
| Q1 24 | $10.9M | $164.6M |
总债务AIMHALO
| Q4 25 | $4.5M | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $2.7M | $1.5B | ||
| Q1 25 | $2.4M | $1.5B | ||
| Q4 24 | $2.8M | $1.5B | ||
| Q3 24 | $3.3M | $1.5B | ||
| Q2 24 | $3.3M | $1.5B | ||
| Q1 24 | $3.3M | $1.5B |
股东权益AIMHALO
| Q4 25 | $-9.8M | $48.8M | ||
| Q3 25 | $-6.1M | $503.9M | ||
| Q2 25 | $-6.5M | $332.7M | ||
| Q1 25 | $-3.9M | $482.3M | ||
| Q4 24 | $-1.3M | $363.8M | ||
| Q3 24 | $2.9M | $452.7M | ||
| Q2 24 | $6.1M | $289.4M | ||
| Q1 24 | $4.8M | $177.8M |
总资产AIMHALO
| Q4 25 | $5.8M | $2.5B | ||
| Q3 25 | $5.5M | $2.2B | ||
| Q2 25 | $4.1M | $2.1B | ||
| Q1 25 | $6.2M | $2.2B | ||
| Q4 24 | $8.6M | $2.1B | ||
| Q3 24 | $13.6M | $2.1B | ||
| Q2 24 | $15.7M | $2.0B | ||
| Q1 24 | $16.2M | $1.8B |
负债/权益比AIMHALO
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | 1.13× | 3.32× | ||
| Q2 24 | 0.54× | 5.19× | ||
| Q1 24 | 0.69× | 8.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $219.0M |
| 自由现金流经营现金流 - 资本支出 | — | $217.6M |
| 自由现金流率自由现金流/营收 | — | 48.2% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $644.6M |
8季度趋势，按日历期对齐
经营现金流AIMHALO
| Q4 25 | $-2.0M | $219.0M | ||
| Q3 25 | $-5.1M | $178.6M | ||
| Q2 25 | $-1.5M | $99.7M | ||
| Q1 25 | $-2.4M | $154.2M | ||
| Q4 24 | $-4.0M | $178.5M | ||
| Q3 24 | $-3.1M | $115.4M | ||
| Q2 24 | $-3.0M | $55.8M | ||
| Q1 24 | $-4.8M | $129.4M |
自由现金流AIMHALO
| Q4 25 | — | $217.6M | ||
| Q3 25 | — | $175.6M | ||
| Q2 25 | — | $98.1M | ||
| Q1 25 | — | $153.3M | ||
| Q4 24 | — | $175.4M | ||
| Q3 24 | — | $113.9M | ||
| Q2 24 | — | $53.2M | ||
| Q1 24 | — | $125.9M |
自由现金流率AIMHALO
| Q4 25 | — | 48.2% | ||
| Q3 25 | — | 49.6% | ||
| Q2 25 | — | 30.1% | ||
| Q1 25 | — | 57.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 39.3% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 64.3% |
资本支出强度AIMHALO
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.8% |
现金转化率AIMHALO
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AIM
暂无分部数据
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
